tiprankstipranks
Antibe Therapeutics (ATBPF)
OTHER OTC:ATBPF
US Market
Holding ATBPF?
Track your performance easily

Antibe Therapeutics (ATBPF) Income Statement

107 Followers

Antibe Therapeutics Income Statement

Last quarter (Q3 2024), Antibe Therapeutics's total revenue was C$―, a decrease of ― from the same quarter last year. In Q3, Antibe Therapeutics's net income was C$-4.21M. See Antibe Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 23Mar 22Mar 21Mar 20Mar 19
Total Revenue
----C$ 9.67MC$ 9.54M
Cost of Revenue
---C$ 6.16MC$ 5.97MC$ 5.99M
Gross Profit
---C$ 3.55MC$ 3.70MC$ 3.55M
Operating Expense
C$ 16.85MC$ 14.43MC$ 23.71MC$ 27.56MC$ 21.03MC$ 15.74M
Operating Income
C$ -16.85MC$ -14.43MC$ -23.71MC$ -27.56MC$ -17.34MC$ -12.19M
Net Non Operating Interest Income Expense
C$ 1.68MC$ 1.34MC$ -290.00KC$ -54.00KC$ 401.00KC$ -493.94K
Other Income Expense
C$ 31.00KC$ 90.00KC$ 5.00KC$ 452.00KC$ -1.31MC$ -95.00K
Pretax Income
C$ -15.18MC$ -13.18MC$ -24.00MC$ -28.15MC$ -19.05MC$ -12.68M
Tax Provision
----C$ 1.00KC$ 134.13K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
C$ -15.50MC$ -13.36MC$ -23.81MC$ -30.60MC$ -19.34MC$ -12.82M
Basic EPS
C$ -0.36C$ -0.37C$ -0.50C$ -0.70C$ -0.70C$ -0.60
Diluted EPS
C$ -0.35C$ -0.37C$ -0.50C$ -0.70C$ -0.70C$ -0.60
Basic Average Shares
C$ 210.50MC$ 52.29MC$ 50.77MC$ 37.25MC$ 27.27MC$ 21.49M
Diluted Average Shares
C$ 218.27MC$ 52.29MC$ 50.77MC$ 37.25MC$ 27.27MC$ 21.49M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
C$ 16.85MC$ 14.43MC$ 23.71MC$ -23.53MC$ -27.00MC$ -21.73M
Net Income From Continuing And Discontinued Operation
C$ -15.50MC$ -13.36MC$ -23.81MC$ -30.60MC$ -19.34MC$ -12.82M
Normalized Income
C$ -11.16MC$ -9.69MC$ -17.64MC$ -20.24MC$ 485.77MC$ -9.32M
Interest Expense
------
EBIT
C$ -15.18MC$ -13.17MC$ -24.00MC$ -28.15MC$ -19.45MC$ -12.16M
EBITDA
C$ -15.18MC$ -13.17MC$ -23.90MC$ -27.67M-C$ -11.74M
Currency in CAD

Antibe Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis